{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:46:23Z","timestamp":1776815183280,"version":"3.51.2"},"reference-count":148,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T00:00:00Z","timestamp":1557273600000},"content-version":"vor","delay-in-days":127,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>With the advent of highly active antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) it has become possible for people with HIV to travel to destinations that may place them at risk of a number of infectious diseases. Prevention of infections by vaccination is therefore of paramount importance for these travellers. However, vaccine responsiveness in HIV-positive individuals is not infrequently reduced compared to HIV-negative individuals. An understanding of the expected immune responses to vaccines in HIV-positive travellers is therefore important in planning the best approach to a pretravel consultation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A PubMed search was performed on HIV or acquired immune deficiency syndrome together with a search for specific vaccines. Review of the literature was performed to develop recommendations on vaccinations for HIV-positive travellers to high-risk destinations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The immune responses to several vaccines are reduced in HIV-positive people. In the case of vaccines for hepatitis A, hepatitis B, influenza, pneumococcus, meningococcus and yellow fever there is a good body of data in the literature showing reduced immune responsiveness and also to help guide appropriate vaccination strategies. For other vaccines like Japanese encephalitis, rabies, typhoid fever, polio and cholera the data are not as robust; however, it is still possible to gain some understanding of the reduced responses seen with these vaccines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This review provides a summary of the immunological responses to commonly used vaccines for the HIV-positive travellers. This information will help guide travel medicine practitioners in making decisions about vaccination and boosting of travellers with HIV.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taz034","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T10:52:07Z","timestamp":1557312727000},"source":"Crossref","is-referenced-by-count":27,"title":["Travel vaccination recommendations and infection risk in HIV-positive travellers"],"prefix":"10.1093","volume":"26","author":[{"given":"Lisa","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Microbiology, Dorevitch Pathology, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan Chang Wei","family":"Lim","sequence":"additional","affiliation":[{"name":"School of Medicine, National University of Ireland, Galway, Ireland"},{"name":"School of Medicine, International Medical University, Kuala Lumpur, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard T","family":"Flaherty","sequence":"additional","affiliation":[{"name":"School of Medicine, National University of Ireland, Galway, Ireland"},{"name":"School of Medicine, International Medical University, Kuala Lumpur, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Torresi","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Peter Doherty Institute, The University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,5,8]]},"reference":[{"key":"2019091012165406100_ref1","first-page":"2","article-title":"HIV infection and travel: pretravel recommendations and health-related risks","volume":"17","author":"Franco-Paredes","year":"2009","journal-title":"Top HIV Med"},{"key":"2019091012165406100_ref2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1258\/0956462971918760","article-title":"Travels with HIV: the compliance and health of HIV-infected adults who travel","volume":"8","author":"Kemper","year":"1997","journal-title":"Int J STD AIDS"},{"key":"2019091012165406100_ref3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1503\/cmaj.1040877","article-title":"Travel patterns and risk behaviour of HIV-positive people travelling internationally","volume":"172","author":"Salit","year":"2005","journal-title":"CMAJ"},{"key":"2019091012165406100_ref4","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/QAI.0b013e31817bebc5","article-title":"Fever after a stay in the tropics: clinical spectrum and outcome in HIV-infected travelers and migrants","volume":"48","author":"Bottieau","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019091012165406100_ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1258\/0956462981921530","article-title":"Pneumococcal vaccination and HIV infection","volume":"9","author":"Moore","year":"1998","journal-title":"Int J STD AIDS"},{"key":"2019091012165406100_ref6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archinte.1991.00400020125026","article-title":"Association between the acquired immunodeficiency syndrome and infection with Salmonella typhi or Salmonella paratyphi in an endemic typhoid area","volume":"151","author":"Gotuzzo","year":"1991","journal-title":"Arch Intern Med"},{"key":"2019091012165406100_ref7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1086\/597006","article-title":"Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients","volume":"48","author":"Veit","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.trstmh.2012.04.002","article-title":"Immunogenicity and safety of yellow fever vaccine among 115 HIV-infected patients after a preventive immunisation campaign in Mali","volume":"106","author":"Sidibe","year":"2012","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2019091012165406100_ref9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/QAI.0b013e318183a9c0","article-title":"Immunological efficacy of a three-dose schedule of hepatitis a vaccine in HIV-infected adults: HEPAVAC study","volume":"49","author":"Launay","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019091012165406100_ref10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QAI.0b013e3181b011f6","article-title":"Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis a vaccine in HIV-infected children on highly active antiretroviral treatment","volume":"52","author":"Weinberg","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019091012165406100_ref11","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1016\/j.vaccine.2009.04.016","article-title":"Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count","volume":"27","author":"Landrum","year":"2009","journal-title":"Vaccine"},{"key":"2019091012165406100_ref12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.amjmed.2018.12.011","article-title":"Vaccination in the adult patient infected with HIV: a review of vaccine efficacy and immunogenicity","volume":"132","author":"El Chaer","year":"2019","journal-title":"Am J Med"},{"key":"2019091012165406100_ref13","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1097\/QAD.0000000000001574","article-title":"HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment","volume":"31","author":"Singh","year":"2017","journal-title":"AIDS"},{"key":"2019091012165406100_ref14","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1086\/433180","article-title":"Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons","volume":"41","author":"Overton","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref15","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1310\/hct1105-332","article-title":"Factors associated with seroconversion after standard dose hepatitis B vaccination and high-dose revaccination among HIV-infected patients","volume":"11","author":"Pettit","year":"2010","journal-title":"HIV Clin Trials"},{"key":"2019091012165406100_ref16","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/infdis\/jis695","article-title":"Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya","volume":"207","author":"Irungu","year":"2013","journal-title":"J Infect Dis"},{"key":"2019091012165406100_ref17","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.1016\/j.vaccine.2017.06.040","article-title":"Long-term protection after hepatitis B vaccination in people living with HIV","volume":"35","author":"Lara","year":"2017","journal-title":"Vaccine"},{"key":"2019091012165406100_ref18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.vaccine.2012.12.047","article-title":"Long-term response rates of successful hepatitis B vaccination in HIV-infected patients","volume":"31","author":"Lopes","year":"2013","journal-title":"Vaccine"},{"key":"2019091012165406100_ref19","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamainternmed.2016.0741","article-title":"Long-term immune response to hepatitis B virus vaccination regimens in adults with human immunodeficiency virus 1: secondary analysis of a randomized clinical trial","volume":"176","author":"Launay","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2019091012165406100_ref20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-6405-3-9","article-title":"Randomized controlled trial of hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses","volume":"3","author":"Cornejo-Juarez","year":"2006","journal-title":"AIDS Res Ther"},{"key":"2019091012165406100_ref21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vaccine.2008.10.040","article-title":"Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients","volume":"27","author":"Cruciani","year":"2009","journal-title":"Vaccine"},{"key":"2019091012165406100_ref22","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jama.2011.351","article-title":"Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial","volume":"305","author":"Launay","year":"2011","journal-title":"JAMA"},{"key":"2019091012165406100_ref23","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1016\/j.vaccine.2012.07.028","article-title":"Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults","volume":"30","author":"Potsch","year":"2012","journal-title":"Vaccine"},{"key":"2019091012165406100_ref24","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.vaccine.2018.02.018","article-title":"Evaluation of a convenient vaccination schedule against hepatitis B in HIV-patients with undetectable HIV viral load","volume":"36","author":"Kourkounti","year":"2018","journal-title":"Vaccine"},{"key":"2019091012165406100_ref25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1468-1293.2007.00473.x","article-title":"Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine","volume":"8","author":"Shafran","year":"2007","journal-title":"HIV Med"},{"key":"2019091012165406100_ref26","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1111\/hiv.12424","article-title":"British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015","volume":"17","author":"Geretti","year":"2016","journal-title":"HIV Med"},{"key":"2019091012165406100_ref27","volume-title":"Health Checks and Vaccinations","author":"Australian Government Department of Foreign Affairs and Trade"},{"key":"2019091012165406100_ref28","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1080\/21645515.2016.1207013","article-title":"Immunization of HIV-infected adult patients\u2014French recommendations","volume":"12","author":"Fresard","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2019091012165406100_ref29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/apc.2009.0340","article-title":"Efficacy of double-dose hepatitis B rescue vaccination in HIV-infected patients","volume":"24","author":"Psevdos","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"2019091012165406100_ref30","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jinf.2014.02.014","article-title":"Determinants of response to repeat hepatitis B vaccination in HIV-infected prior non-responders","volume":"69","author":"Rowley","year":"2014","journal-title":"J Infect"},{"key":"2019091012165406100_ref31","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1473-3099(15)00220-0","article-title":"Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial","volume":"15","author":"Rey","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2019091012165406100_ref32","doi-asserted-by":"crossref","first-page":"e0184128","DOI":"10.1371\/journal.pone.0184128","article-title":"Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: results of a prospective Italian study","volume":"12","author":"Morsica","year":"2017","journal-title":"PLoS One"},{"key":"2019091012165406100_ref33","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/infdis\/jiq137","article-title":"A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients","volume":"203","author":"de Vries-Sluijs","year":"2011","journal-title":"J Infect Dis"},{"key":"2019091012165406100_ref34","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1080\/21645515.2015.1055424","article-title":"Hepatitis B and A vaccination in HIV-infected adults: a review","volume":"11","author":"Mena","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"2019091012165406100_ref35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2016.1277844","article-title":"Hepatitis B virus vaccination in HIV-infected people: a review","volume":"13","author":"Catherine","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2019091012165406100_ref36","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/429302","article-title":"Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies","volume":"191","author":"Gandhi","year":"2005","journal-title":"J Infect Dis"},{"key":"2019091012165406100_ref37","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1086\/651422","article-title":"Serologic response to hepatitis B vaccination in HIV-infected patients with isolated positivity for antibodies to hepatitis B core antigen","volume":"50","author":"Chakvetadze","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref38","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jinf.2012.03.009","article-title":"Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen","volume":"65","author":"Kaech","year":"2012","journal-title":"J Infect"},{"key":"2019091012165406100_ref39","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.3748\/wjg.v23.i20.3589","article-title":"Hepatitis A virus infection and hepatitis a vaccination in human immunodeficiency virus-positive patients: a review","volume":"23","author":"Lin","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2019091012165406100_ref40","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1086\/424666","article-title":"Safety and immunogenicity of an inactivated hepatitis a vaccine among HIV-infected subjects","volume":"39","author":"Wallace","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref41","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.vaccine.2005.07.102","article-title":"Efficacy of inactivated hepatitis A vaccine in HIV-infected patients: a hierarchical bayesian meta-analysis","volume":"24","author":"Shire","year":"2006","journal-title":"Vaccine"},{"key":"2019091012165406100_ref42","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.vaccine.2012.12.045","article-title":"Hepatitis A vaccine response in HIV-infected patients: are TWINRIX and HAVRIX interchangeable?","volume":"31","author":"Jimenez","year":"2013","journal-title":"Vaccine"},{"key":"2019091012165406100_ref43","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1002\/hep.26210","article-title":"Comparative effectiveness of two doses versus three doses of hepatitis A vaccine in human immunodeficiency virus-infected and -uninfected men who have sex with men","volume":"57","author":"Tseng","year":"2013","journal-title":"Hepatology"},{"key":"2019091012165406100_ref44","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archinte.161.3.441","article-title":"Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome","volume":"161","author":"Lin","year":"2001","journal-title":"Arch Intern Med"},{"key":"2019091012165406100_ref45","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/00126334-200311010-00008","article-title":"Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection","volume":"34","author":"Neuzil","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019091012165406100_ref46","first-page":"1","article-title":"Travellers and influenza: risks and prevention","volume":"4","author":"Goeijenbier","year":"2016","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref47","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1471-2334-6-138","article-title":"Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis","volume":"6","author":"Atashili","year":"2006","journal-title":"BMC Infect Dis"},{"key":"2019091012165406100_ref48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/irv.12351","article-title":"A review of the changes to the licensing of influenza vaccines in Europe","volume":"10","author":"Wijnans","year":"2016","journal-title":"Influenza Other Respi Viruses"},{"key":"2019091012165406100_ref49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1750-2659.2011.00268.x","article-title":"Quantitative review of antibody response to inactivated seasonal influenza vaccines","volume":"6","author":"Seidman","year":"2012","journal-title":"Influenza Other Respi Viruses"},{"key":"2019091012165406100_ref50","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1097\/QAD.0000000000000772","article-title":"The impact of vaccination on the breadth and magnitude of the antibody response to influenza A viruses in HIV-infected individuals","volume":"29","author":"Kohler","year":"2015","journal-title":"AIDS"},{"key":"2019091012165406100_ref51","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1080\/21645515.2016.1246636","article-title":"Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore","volume":"13","author":"Lau","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2019091012165406100_ref52","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3109\/00365548.2014.922695","article-title":"Durability of protective antibody titres is not enhanced by a two-dose schedule of an ASO3-adjuvanted pandemic H1N1 influenza vaccine in adult HIV-1-infected patients","volume":"46","author":"Bickel","year":"2014","journal-title":"Scand J Infect Dis"},{"key":"2019091012165406100_ref53","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1128\/JVI.00285-16","article-title":"Antibody responses with Fc-mediated functions after vaccination of HIV-infected subjects with trivalent influenza vaccine","volume":"90","author":"Kristensen","year":"2016","journal-title":"J Virol"},{"key":"2019091012165406100_ref54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1310\/hct1404-175","article-title":"Immune response after a single dose of the 2010\/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls","volume":"14","author":"Bickel","year":"2013","journal-title":"HIV Clin Trials"},{"key":"2019091012165406100_ref55","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/598193","article-title":"Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients","volume":"48","author":"Evison","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref56","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-158-1-201301010-00005","article-title":"Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial","volume":"158","author":"McKittrick","year":"2013","journal-title":"Ann Intern Med"},{"key":"2019091012165406100_ref57","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1016\/j.vaccine.2016.04.053","article-title":"Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection","volume":"34","author":"Hakim","year":"2016","journal-title":"Vaccine"},{"key":"2019091012165406100_ref58","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/jama.1989.03430060075029","article-title":"The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine","volume":"262","author":"Miotti","year":"1989","journal-title":"JAMA"},{"key":"2019091012165406100_ref59","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1016\/S0264-410X(00)00079-7","article-title":"Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study","volume":"18","author":"Kroon","year":"2000","journal-title":"Vaccine"},{"key":"2019091012165406100_ref60","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1310\/hct1301-23","article-title":"High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults","volume":"13","author":"Cooper","year":"2012","journal-title":"HIV Clin Trials"},{"key":"2019091012165406100_ref61","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/S0264-410X(03)00408-0","article-title":"Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy","volume":"21","author":"Iorio","year":"2003","journal-title":"Vaccine"},{"key":"2019091012165406100_ref62","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/CVI.00316-07","article-title":"Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults","volume":"15","author":"Durando","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"2019091012165406100_ref63","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1468-1293.2011.00961.x","article-title":"Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients","volume":"13","author":"Calmy","year":"2012","journal-title":"HIV Med"},{"key":"2019091012165406100_ref64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2172-13-49","article-title":"Responses to pandemic ASO3-adjuvanted A\/California\/07\/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals","volume":"13","author":"Kelly","year":"2012","journal-title":"BMC Immunol"},{"key":"2019091012165406100_ref65","doi-asserted-by":"crossref","first-page":"7067","DOI":"10.1016\/j.vaccine.2012.09.052","article-title":"Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults","volume":"30","author":"Nielsen","year":"2012","journal-title":"Vaccine"},{"key":"2019091012165406100_ref66","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/QAD.0b013e328359f27a","article-title":"Long-term immunogenicity of two doses of 2009 A\/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults","volume":"27","author":"Durier","year":"2013","journal-title":"AIDS"},{"key":"2019091012165406100_ref67","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s10875-014-0054-z","article-title":"High level antibody avidity is achieved in HIV-seropositive recipients of an inactivated split adjuvanted (AS03A) influenza vaccine","volume":"34","author":"Yam","year":"2014","journal-title":"J Clin Immunol"},{"key":"2019091012165406100_ref68","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.immuni.2010.10.007","article-title":"Designing vaccines based on biology of human dendritic cell subsets","volume":"33","author":"Palucka","year":"2010","journal-title":"Immunity"},{"key":"2019091012165406100_ref69","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1016\/j.vaccine.2009.02.053","article-title":"Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible","volume":"27","author":"Gelinck","year":"2009","journal-title":"Vaccine"},{"key":"2019091012165406100_ref70","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/cid\/civ884","article-title":"Randomized controlled trial to compare immunogenicity of standard-dose intramuscular versus intradermal trivalent inactivated influenza vaccine in HIV-infected men who have sex with men in Bangkok, Thailand","volume":"62","author":"Garg","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref71","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/21645515.2015.1076599","article-title":"Safety and immunogenicity of influenza vaccine among HIV-infected adults: conventional vaccine vs. intradermal vaccine","volume":"12","author":"Seo","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2019091012165406100_ref72","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1086\/315246","article-title":"Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults","volume":"181","author":"King","year":"2000","journal-title":"J Infect Dis"},{"key":"2019091012165406100_ref73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcv.2017.08.009","article-title":"Live versus attenuated influenza vaccine uptake and post-vaccination influenza-like illness outcomes in HIV-infected US Air Force members","volume":"95","author":"Menegay","year":"2017","journal-title":"J Clin Virol"},{"key":"2019091012165406100_ref74","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1293.2009.00695.x","article-title":"Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease","volume":"10","author":"Imaz","year":"2009","journal-title":"HIV Med"},{"key":"2019091012165406100_ref75","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/QAD.0b013e32833d46fd","article-title":"Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization","volume":"24","author":"Cohen","year":"2010","journal-title":"AIDS"},{"key":"2019091012165406100_ref76","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/QAI.0b013e3181e8ed15","article-title":"Hospitalizations for invasive pneumococcal disease among HIV-1-infected adolescents and adults in the United States in the era of highly active antiretroviral therapy and the conjugate pneumococcal vaccine","volume":"55","author":"Kourtis","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019091012165406100_ref77","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1016\/j.vaccine.2014.07.086","article-title":"Pneumococcal vaccination in people living with HIV","volume":"33","author":"Thornhill","year":"2015","journal-title":"Vaccine"},{"key":"2019091012165406100_ref78","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/apc.2016.0165","article-title":"Invasive pneumococcal disease among HIV-infected and HIV-uninfected adults in a large integrated healthcare system","volume":"30","author":"Marcus","year":"2016","journal-title":"AIDS Patient Care STDS"},{"key":"2019091012165406100_ref79","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/QAI.0000000000001054","article-title":"Brief report: immunization of HIV-infected adults in the UK with Haemophilus influenzae b\/meningococcal C Glycoconjugate and pneumococcal polysaccharide vaccines","volume":"73","author":"MacLennan","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019091012165406100_ref80","first-page":"pii:421","article-title":"Response to pneumococcal polysaccharide vaccination in HIV-positive individuals on long term highly active antiretroviral therapy","volume":"6","author":"Iyer","year":"2015","journal-title":"J AIDS Clin Res"},{"key":"2019091012165406100_ref81","doi-asserted-by":"crossref","first-page":"e0176641","DOI":"10.1371\/journal.pone.0176641","article-title":"Production of IgG antibodies to pneumococcal polysaccharides is associated with expansion of ICOS+ circulating memory T follicular-helper cells which is impaired by HIV infection","volume":"12","author":"Abudulai","year":"2017","journal-title":"PLoS One"},{"key":"2019091012165406100_ref82","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0956462412472450","article-title":"Immunization against pneumococcal disease in HIV-infected patients: conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147)","volume":"24","author":"Slayter","year":"2013","journal-title":"Int J STD AIDS"},{"key":"2019091012165406100_ref83","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/infdis\/jiv349","article-title":"No benefit to delaying pneumococcal polysaccharide vaccination in HIV-positive adults","volume":"212","author":"Leggat","year":"2015","journal-title":"J Infect Dis"},{"key":"2019091012165406100_ref84","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/infdis\/jiu819","article-title":"Quantitative and qualitative antibody responses to immunization with the pneumococcal polysaccharide vaccine in HIV-infected patients after initiation of antiretroviral treatment: results from a randomized clinical trial","volume":"211","author":"Rodriguez-Barradas","year":"2015","journal-title":"J Infect Dis"},{"key":"2019091012165406100_ref85","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(00)02377-1","article-title":"23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial","volume":"355","author":"French","year":"2000","journal-title":"Lancet"},{"key":"2019091012165406100_ref86","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1468-1293.2010.00892.x","article-title":"The effectiveness of pneumococcal polysaccharide vaccination in HIV-infected adults: a systematic review","volume":"12","author":"Pedersen","year":"2011","journal-title":"HIV Med"},{"key":"2019091012165406100_ref87","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1136\/bmj.316.7144.1571","article-title":"Science commentary: why conjugate vaccines protect longer","volume":"316","author":"Berger","year":"1998","journal-title":"BMJ"},{"key":"2019091012165406100_ref88","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/17476348.2017.1289841","article-title":"HIV-related pneumococcal disease prevention in adults","volume":"11","author":"Feldman","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"2019091012165406100_ref89","doi-asserted-by":"crossref","first-page":"20631","DOI":"10.7448\/IAS.19.1.20631","article-title":"Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy","volume":"19","author":"Cheng","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2019091012165406100_ref90","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/QAD.0000000000000689","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination","volume":"29","author":"Bhorat","year":"2015","journal-title":"AIDS"},{"key":"2019091012165406100_ref91","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1016\/j.vaccine.2013.04.065","article-title":"Immunogenicity and safety of pneumococcal conjugate polysaccharide and free polysaccharide vaccines alone or combined in HIV-infected adults in Brazil","volume":"31","author":"Ho","year":"2013","journal-title":"Vaccine"},{"key":"2019091012165406100_ref92","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4161\/hv.22836","article-title":"Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy","volume":"9","author":"Lu","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"2019091012165406100_ref93","doi-asserted-by":"crossref","first-page":"e0156523","DOI":"10.1371\/journal.pone.0156523","article-title":"Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: a pilot, prospective controlled study","volume":"11","author":"Lombardi","year":"2016","journal-title":"PLoS One"},{"key":"2019091012165406100_ref94","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1086\/339044","article-title":"Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses","volume":"34","author":"Tasker","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref95","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1080\/21645515.2016.1160987","article-title":"Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults","volume":"12","author":"Rossheim","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"2019091012165406100_ref96","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/infdis\/jiu631","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine","volume":"212","author":"Glesby","year":"2015","journal-title":"J Infect Dis"},{"key":"2019091012165406100_ref97","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1097\/QAD.0b013e3282887e91","article-title":"Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults","volume":"21","author":"Lesprit","year":"2007","journal-title":"AIDS"},{"key":"2019091012165406100_ref98","doi-asserted-by":"crossref","first-page":"32076","DOI":"10.1038\/srep32076","article-title":"Immunological efficacy of pneumococcal vaccine strategies in HIV-infected adults: a randomized clinical trial","volume":"6","author":"Sadlier","year":"2016","journal-title":"Sci Rep"},{"key":"2019091012165406100_ref99","doi-asserted-by":"crossref","first-page":"tax006","DOI":"10.1093\/jtm\/tax006","article-title":"Tetanus\u2013diphtheria\u2013pertussis vaccine may suppress the immune response to subsequent immunization with pneumococcal CRM197-conjugate vaccine (coadministered with quadrivalent meningococcal TT-conjugate vaccine): a randomized, controlled trial","volume":"24","author":"Tashani","year":"2017","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref100","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-160-1-201401070-00731","article-title":"Elevated risk for invasive meningococcal disease among persons with HIV","volume":"160","author":"Miller","year":"2014","journal-title":"Ann Intern Med"},{"key":"2019091012165406100_ref101","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/cid\/cix438","article-title":"Increased risk for meningococcal disease among men who have sex with men in the United States, 2012\u20132015","volume":"65","author":"Folaranmi","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref102","volume-title":"CDC Health Information for International Travel 2018","author":"Center For Diseases Control and Prevention","year":"2018"},{"key":"2019091012165406100_ref103","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0924-8579(02)00284-4","article-title":"Meningococcal disease and travel","volume":"21","author":"Wilder-Smith","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"2019091012165406100_ref104","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijid.2016.04.007","article-title":"Meningococcal disease during the Hajj and Umrah mass gatherings","volume":"47","author":"Yezli","year":"2016","journal-title":"Int J Infect Dis"},{"key":"2019091012165406100_ref105","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1016\/j.vaccine.2012.06.069","article-title":"Immunogenicity of a meningococcal serogroup C conjugate vaccine in HIV-infected children, adolescents, and young adults","volume":"30","author":"Bertolini","year":"2012","journal-title":"Vaccine"},{"key":"2019091012165406100_ref106","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/INF.0b013e318236c67b","article-title":"Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children","volume":"31","author":"Siberry","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"2019091012165406100_ref107","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jpeds.2012.04.005","article-title":"Immunogenicity and safety of 1 vs 2 doses of quadrivalent meningococcal conjugate vaccine in youth infected with human immunodeficiency virus","volume":"161","author":"Lujan-Zilbermann","year":"2012","journal-title":"J Pediatr"},{"key":"2019091012165406100_ref108","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1093\/jpids\/piw094","article-title":"Immunogenicity of a booster dose of quadrivalent meningococcal conjugate vaccine in previously immunized HIV-infected children and youth","volume":"6","author":"Warshaw","year":"2017","journal-title":"J Pediatric Infect Dis"},{"key":"2019091012165406100_ref109","first-page":"tay112","article-title":"Interaction of meningococcal conjugate vaccines with other conjugate or diphtheria-tetanus containing vaccines","volume":"25","author":"Badahdah","year":"2018","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref110","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/jtm\/tay006","article-title":"Recent and historical trends in the epidemiology of Japanese encephalitis and its implication for risk assessment in travellers","volume":"25","author":"Lindquist","year":"2018","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref111","doi-asserted-by":"crossref","first-page":"8257","DOI":"10.1016\/j.vaccine.2007.09.052","article-title":"Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy","volume":"25","author":"Puthanakit","year":"2007","journal-title":"Vaccine"},{"key":"2019091012165406100_ref112","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1016\/j.vaccine.2010.02.108","article-title":"A comparative study of the serological response to Japanese encephalitis vaccine in HIV-infected and uninfected Thai children","volume":"28","author":"Chokephaibulkit","year":"2010","journal-title":"Vaccine"},{"key":"2019091012165406100_ref113","doi-asserted-by":"crossref","first-page":"5900","DOI":"10.1016\/j.vaccine.2010.06.048","article-title":"A 3-year follow-up of antibody response in HIV-infected children with immune recovery vaccinated with inactivated Japanese encephalitis vaccine","volume":"28","author":"Puthanakit","year":"2010","journal-title":"Vaccine"},{"key":"2019091012165406100_ref114","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.vaccine.2015.07.057","article-title":"Japanese encephalitis vaccines: WHO position paper, February 2015\u2014recommendations","volume":"34","author":"WHO","year":"2016","journal-title":"Vaccine"},{"key":"2019091012165406100_ref115","doi-asserted-by":"crossref","first-page":"taw045","DOI":"10.1093\/jtm\/taw045","article-title":"Adverse event reports following yellow fever vaccination, 2007\u201313","volume":"23","author":"Lindsey","year":"2016","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref116","first-page":"131","article-title":"Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection","volume":"85","author":"Kengsakul","year":"2002","journal-title":"J Med Assoc Thai"},{"key":"2019091012165406100_ref117","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/00002030-200403260-00020","article-title":"Yellow fever vaccine is safe and effective in HIV-infected patients","volume":"18","author":"Tattevin","year":"2004","journal-title":"AIDS"},{"key":"2019091012165406100_ref118","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/QAI.0b013e318249de59","article-title":"Plasma HIV-RNA is the key determinant of long-term antibody persistence after yellow fever immunization in a cohort of 364 HIV-infected patients","volume":"59","author":"Pacanowski","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019091012165406100_ref119","doi-asserted-by":"crossref","first-page":"e0005219","DOI":"10.1371\/journal.pntd.0005219","article-title":"CD4\/CD8 ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients","volume":"10","author":"Avelino-Silva","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2019091012165406100_ref120","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/cid\/cix960","article-title":"Long-term immune response to yellow fever vaccination in human immunodeficiency virus (HIV)-infected individuals depends on HIV RNA suppression status: implications for vaccination schedule","volume":"66","author":"Veit","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref121","doi-asserted-by":"crossref","first-page":"tay108","DOI":"10.1093\/jtm\/tay108","article-title":"Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers","volume":"25","author":"Lindsey","year":"2018","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref122","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/trstmh\/trt014","article-title":"Demographic profile of sylvatic yellow fever in Brazil from 1973 to 2008","volume":"107","author":"Camara","year":"2013","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2019091012165406100_ref123","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1080\/14760584.2016.1198259","article-title":"Questions regarding the safety and duration of immunity following live yellow fever vaccination","volume":"15","author":"Amanna","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2019091012165406100_ref124","doi-asserted-by":"crossref","first-page":"tay130","DOI":"10.1093\/jtm\/tay130","article-title":"Ten yearly yellow fever booster vaccinations may still be justified","volume":"25","author":"Plotkin","year":"2018","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0956462412472309","article-title":"Does increased hepatitis B vaccination dose lead to a better immune response in HIV-infected patients than standard dose vaccination: a meta-analysis?","volume":"24","author":"Ni","year":"2013","journal-title":"Int J STD AIDS"},{"key":"2019091012165406100_ref126","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1016\/j.vaccine.2004.11.057","article-title":"Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose","volume":"23","author":"Fonseca","year":"2005","journal-title":"Vaccine"},{"key":"2019091012165406100_ref127","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0b013e318203e9f2","article-title":"Hepatitis B vaccination in HIV-infected youth: a randomized trial of three regimens","volume":"56","author":"Flynn","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019091012165406100_ref128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.vaccine.2004.05.010","article-title":"Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects","volume":"23","author":"Ristola","year":"2004","journal-title":"Vaccine"},{"key":"2019091012165406100_ref129","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/01.aids.0000183514.37513.d2","article-title":"CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults","volume":"19","author":"Cooper","year":"2005","journal-title":"AIDS"},{"key":"2019091012165406100_ref130","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-8518-6-4","article-title":"CpG increases vaccine antigen-specific cell-mediated immunity when administered with hepatitis B vaccine in HIV infection","volume":"6","author":"Angel","year":"2008","journal-title":"J Immune Based Ther Vaccines"},{"key":"2019091012165406100_ref131","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1016\/j.vaccine.2010.06.030","article-title":"Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220","volume":"28","author":"Overton","year":"2010","journal-title":"Vaccine"},{"key":"2019091012165406100_ref132","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/clinids\/21.5.1197","article-title":"Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus","volume":"21","author":"Kroon","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref133","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00002030-199212000-00007","article-title":"Immunization in children with HIV seropositivity at birth: antibody response to polio vaccine and tetanus toxoid","volume":"6","author":"Barbi","year":"1992","journal-title":"AIDS"},{"key":"2019091012165406100_ref134","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/infdis\/jiu841","article-title":"Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV-infected adults","volume":"211","author":"Troy","year":"2015","journal-title":"J Infect Dis"},{"key":"2019091012165406100_ref135","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/S0264-410X(99)00167-X","article-title":"Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi)","volume":"17","author":"Kroon","year":"1999","journal-title":"Vaccine"},{"key":"2019091012165406100_ref136","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2310\/7060.2000.00005","article-title":"Typhoid fever in group travelers: opportunity for studying vaccine efficacy","volume":"7","author":"Cobelens","year":"2000","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref137","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jinf.2008.03.012","article-title":"Salmonella infections in immunocompromised adults","volume":"56","author":"Gordon","year":"2008","journal-title":"J Infect"},{"key":"2019091012165406100_ref138","first-page":"tay090","article-title":"Typhoid vaccine responses in travellers treated with immunosuppressive therapy","volume":"25","author":"Jin","year":"2018","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref139","doi-asserted-by":"crossref","first-page":"tay073","DOI":"10.1093\/jtm\/tay073","article-title":"S. typhi Vi capsular polysaccharide vaccine-induced humoral immunity in travellers with immunosuppressive therapy for rheumatoid disease","volume":"26","author":"von Asmuth","year":"2019","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1708-8305.2012.00673.x","article-title":"Business travelers\u2019 risk perception of infectious diseases: where are the knowledge gaps, and how serious are they?","volume":"20","author":"Wynberg","year":"2013","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref141","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/QAD.0b013e328331a43b","article-title":"Restoration of the antibody response upon rabies vaccination in HIV-infected patients treated with HAART","volume":"23","author":"Gelinck","year":"2009","journal-title":"AIDS"},{"key":"2019091012165406100_ref142","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1016\/j.vaccine.2009.03.027","article-title":"Antibody response to an eight-site intradermal rabies vaccination in patients infected with human immunodeficiency virus","volume":"27","author":"Sirikwin","year":"2009","journal-title":"Vaccine"},{"key":"2019091012165406100_ref143","doi-asserted-by":"crossref","first-page":"E122","DOI":"10.1086\/324087","article-title":"Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts","volume":"33","author":"Tantawichien","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref144","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1086\/313610","article-title":"Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1","volume":"30","author":"Thisyakorn","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref145","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1086\/517241","article-title":"Postexposure rabies vaccination in patients infected with human immunodeficiency virus","volume":"28","author":"Jaijaroensup","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2019091012165406100_ref146","first-page":"tay119","article-title":"Preventing rabies: the new WHO recommendations and their impact on travel medicine practice","volume":"25","author":"Shlim","year":"2018","journal-title":"J Travel Med"},{"key":"2019091012165406100_ref147","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/infdis\/jiv108","article-title":"Immunogenicity of the bivalent oral cholera vaccine Shanchol in Haitian adults with HIV infection","volume":"212","author":"Ivers","year":"2015","journal-title":"J Infect Dis"},{"key":"2019091012165406100_ref148","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMoa043323","article-title":"Effectiveness of mass oral cholera vaccination in Beira, Mozambique","volume":"352","author":"Lucas","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taz034\/28841893\/taz034.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jtm\/article-pdf\/26\/6\/taz034\/29452813\/taz034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T17:17:16Z","timestamp":1568135836000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taz034\/5486056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":148,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,5,8]]},"published-print":{"date-parts":[[2019,9,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taz034","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019]]},"published":{"date-parts":[[2019]]},"article-number":"taz034"}}